Profil
Alexey Wolfson is the founder of Advirna LLC, where he currently holds the title of Chief Executive Officer since 2007.
He is also the founder of MirImmune, Inc., where he currently holds the title of Secretary & Director since 2015.
Aktive Positionen von Alexey Wolfson
| Unternehmen | Position | Beginn |
|---|---|---|
MirImmune, Inc.
 MirImmune, Inc. BiotechnologyHealth Technology MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA. | Gründer | 18.05.2015 |
Advirna LLC
 Advirna LLC BiotechnologyHealth Technology Advirna LLC engages in the development of new nucleic-based technologies for therapeutic and research use. It offers validated self-deliverable ribonucleic acid (SDRNA), in vivo SDRNA, transfection controls, starter kits, and custom SDRNA. The company was founded by Anastasia Khvorova and Alexey Wolfson in 2007 and is headquartered in Worcester, MA. | Vorstandsvorsitzender | 01.01.2007 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Advirna LLC
Advirna LLC BiotechnologyHealth Technology Advirna LLC engages in the development of new nucleic-based technologies for therapeutic and research use. It offers validated self-deliverable ribonucleic acid (SDRNA), in vivo SDRNA, transfection controls, starter kits, and custom SDRNA. The company was founded by Anastasia Khvorova and Alexey Wolfson in 2007 and is headquartered in Worcester, MA. | Health Technology |
MirImmune, Inc.
MirImmune, Inc. BiotechnologyHealth Technology MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA. | Health Technology |
